Warby Parker (WRBY) Non-Current Deffered Revenue (2020 - 2021)
Warby Parker (WRBY) posted Non-Current Deffered Revenue of $36.5 million for Q4 2021, up 17.97% on a QoQ basis from $31.0 million in Q3 2021, and up 30.53% year-over-year from $28.0 million in Q4 2020.
Warby Parker (WRBY) Non-Current Deffered Revenue (2020 - 2021) Analysis & Trends
Warby Parker's Non-Current Deffered Revenue history runs 2 years deep, the most recent figure standing at $36.5 million for Q4 2021.
- Quarterly Non-Current Deffered Revenue rose 30.53% year-over-year to $36.5 million in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $36.5 million (up 30.53% YoY) and the FY2021 annual result came in at $36.5 million, up 30.53% from the prior year.
- Non-Current Deffered Revenue was $36.5 million for Q4 2021 at Warby Parker, up from $31.0 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $36.5 million in Q4 2021 and bottomed at $28.0 million in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alcon | 32,734,969.19 Bn | 32,734,967.53 Bn | 1.53 Bn | - |
| 2 | Intuitive Surgical | 117.50 Bn | 112.41 Bn | 1.96 Bn | - |
| 3 | Becton Dickinson | 42.93 Bn | 42.11 Bn | 2.15 Bn | - |
| 4 | Medline | 30.82 Bn | 36.66 Bn | 1.84 Bn | - |
| 5 | Resmed | 27.90 Bn | 26.23 Bn | 890.98 Mn | 163.15 Mn |
| 6 | West Pharmaceutical Services | 26.76 Bn | 26.23 Bn | 329.20 Mn | 13.90 Mn |
| 7 | Cooper Companies | 15.30 Bn | 15.16 Bn | 735.40 Mn | 208.80 Mn |
| 8 | Solventum | 13.46 Bn | 12.90 Bn | 1.10 Bn | - |
| 9 | Align Technology | 12.02 Bn | 10.96 Bn | 736.59 Mn | - |
| 10 | Warby Parker | 3.00 Bn | 2.71 Bn | 131.04 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 36.54 Mn |
| Sep 30, 2021 | 30.98 Mn |
| Dec 31, 2020 | 28.00 Mn |